Afya Limited Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 7% and net income rose 7% year-over-year in the first half of 2026, with strong cash generation and disciplined capital allocation leading to over 100% of Free Cash Flow to Equity returned to shareholders. Competitive and regulatory factors impacted some segments, but guidance remains unchanged.
-
Revenue rose 8% year-over-year to BRL 1.013 billion, with net income up 2% and strong cash flow. Growth was driven by higher medical course tickets, expanding health programs, and investments in digital solutions, despite margin pressure from increased costs.
Fiscal Year 2025
-
Delivered strong 2025 results with 12% revenue and 18% net income growth, robust cash flow, and a 19% EPS increase. 2026 guidance anticipates continued growth, with investments in technology and integration expected to impact margins.
-
Strong revenue and profit growth continued, with margin expansion and robust cash generation. Capital allocation remains flexible, balancing M&A, buybacks, and dividends, while tax rates are expected to rise due to new regulations.
-
The event highlighted a robust integrated ecosystem spanning medical education, digital solutions, and clinical practice, with strong financial performance and ambitious growth targets for 2025. Key innovations include AI-powered learning tools, simulation centers, and digital platforms, while expansion in continuing education and B2P segments is expected to drive future growth.
-
Q2 and H1 2025 saw double-digit revenue and EBITDA growth, margin expansion, and strong cash flow, driven by robust performance across all segments and disciplined capital allocation. Guidance for 2025 is reaffirmed, with tax and competitive pressures being actively managed.
-
Revenue grew 16% year-over-year, with adjusted EBITDA up 24% and net income up 23%. Strong operational performance drove margin expansion, robust cash flow, and reduced net debt. Guidance remains unchanged, with continued growth expected across all segments.
Fiscal Year 2024
-
Net revenue and adjusted EBITDA grew strongly in 2024, with robust cash flow and margin expansion. Dividend payout of 20% of net income was announced, and 2025 guidance projects continued growth in revenue and EBITDA. M&A and organic expansion remain key priorities.
-
Net revenue and adjusted EBITDA grew strongly year-over-year, driven by expansion in medical seats, acquisitions, and operational efficiencies. Margin expansion is expected to continue, with robust M&A activity and strong demand for medical programs supporting future growth.
-
The event highlighted a physician-centric ecosystem integrating education, digital solutions, and industry partnerships, driving robust growth through seat expansion, disciplined M&A, and innovation. Strong cash generation, brand reputation, and a focus on social impact and digital transformation underpin long-term sustainability.
-
Q2 2024 saw double-digit revenue and EBITDA growth, margin expansion, and strong cash flow, driven by robust performance across all segments and successful integration of recent acquisitions. Updated 2024 guidance reflects higher revenue and EBITDA expectations.